Biogen — Jul 31, 2025 release

during Q2 Advanced and expanded late-stage pipeline through execution of multiple milestones during Q2 • Salanersen to advance to registrational stage based on exciting interim Phase 1b results in SMA • Felzartamab Phase 3 studies initiated in IgA nephropathy and primary membranous nephropathy • Dapirolizumab pegol Phase 3 data presented at EULAR show improvement in fatigue and reduction of disease activity in SLE • SKYCLARYS Phase 3 study initiated in children with Friedreich ataxia between the ages of 2 to <16 Biogen increased full year 2025 guidance to reflect stronger expected business outlook for the full year • Increased expected full year 2025 Non-GAAP diluted EPS to between $15.50 and $16.00, up from between $14.50 and $15.50 previously • Increased expected full year 2025 total revenue to be approximately flat, at constant currency, versus full year 2024, up from a mid-single digit decline previously Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2025 financial results. Commenting on the results, President and Chief Executive Officer Christopher A. Viehbacher said: "We delivered another quarter of strong execution against our strategy to transform our portfolio and build the new Biogen. Our performance reflects robust financial results, ongoing cost discipline, continued growth of our launch products, and meaningful strides expanding and advancing our late-stage pipeline. We are now progressing salanersen to registrational studies in SMA following exciting interim Phase 1b results, and have initiated all three Phase 3 studies for felzartamab in rare kidney disease. These achievements reinforce our commitment to building a stronger company, with the potential for sustainable growth and long-term value for our shareholders." 1 Financial Highlights Q2 '25 Q2 '24 △ r (CC * ) Total Revenue (in millions) $2,646 $2,465 7% 8% GAAP diluted EPS $4.33 $4.00 8% N/A Non-GAAP diluted EPS $5.47 $5.28 4% N/A Note: Percent changes represented as favorable/(unfavorable) versus the prior year period. N/A = not applicable. * Percentage chan